Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of Nuvation Bio Inc (NYSE: NUVB) was $7.84 for the day, down -2.00% from the previous closing price of $8.0. In other words, the price has decreased by -$2.00 from its previous closing price. On the day, 5.99 million shares were traded. NUVB stock price reached its highest trading level at $8.05 during the session, while it also had its lowest trading level at $7.8.
Ratios:
Our analysis of NUVB’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.39 and its Current Ratio is at 8.48. In the meantime, Its Debt-to-Equity ratio is 0.64 whereas as Long-Term Debt/Eq ratio is at 0.60.
On November 19, 2025, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $12.
On September 30, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $10.Jefferies initiated its Buy rating on September 30, 2025, with a $10 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 01 ’25 when Liu Dongfang sold 150,000 shares for $7.82 per share. The transaction valued at 1,173,255 led to the insider holds 18,000 shares of the business.
DONGFANG LIU bought 150,000 shares of NUVB for $1,173,255 on Dec 01 ’25. On Nov 26 ’25, another insider, Liu Dongfang, who serves as the CHIEF MEDICAL OFFICER of the company, sold 10,000 shares for $8.00 each. As a result, the insider received 80,000 and left with 18,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NUVB now has a Market Capitalization of 2687814144 and an Enterprise Value of 2196317184. For the stock, the TTM Price-to-Sale (P/S) ratio is 100.77 while its Price-to-Book (P/B) ratio in mrq is 8.25. Its current Enterprise Value per Revenue stands at 82.111 whereas that against EBITDA is -9.485.
Stock Price History:
The Beta on a monthly basis for NUVB is 1.56, which has changed by 2.041825 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, NUVB has reached a high of $8.95, while it has fallen to a 52-week low of $1.54. The 50-Day Moving Average of the stock is 44.72%, while the 200-Day Moving Average is calculated to be 152.25%.
Shares Statistics:
NUVB traded an average of 8.60M shares per day over the past three months and 6317130 shares per day over the past ten days. A total of 341.76M shares are outstanding, with a floating share count of 239.22M. Insiders hold about 30.43% of the company’s shares, while institutions hold 53.83% stake in the company. Shares short for NUVB as of 1764288000 were 52605709 with a Short Ratio of 6.12, compared to 1761868800 on 67690040. Therefore, it implies a Short% of Shares Outstanding of 52605709 and a Short% of Float of 25.0.
Earnings Estimates
The company has 1.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.12 and low estimates of -$0.47.
Analysts are recommending an EPS of between -$0.45 and -$0.45 for the fiscal current year, implying an average EPS of -$0.45. EPS for the following year is -$0.28, with 1.0 analysts recommending between -$0.28 and -$0.28.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 8 analysts. It ranges from a high estimate of $49.8M to a low estimate of $14.37M. As of. The current estimate, Nuvation Bio Inc’s year-ago sales were $5.71MFor the next quarter, 8 analysts are estimating revenue of $29.37M. There is a high estimate of $36.7M for the next quarter, whereas the lowest estimate is $22.3M.
A total of 9 analysts have provided revenue estimates for NUVB’s current fiscal year. The highest revenue estimate was $70.8M, while the lowest revenue estimate was $35.41M, resulting in an average revenue estimate of $53.93M. In the same quarter a year ago, actual revenue was $7.87MBased on 9 analysts’ estimates, the company’s revenue will be $169.46M in the next fiscal year. The high estimate is $207.7M and the low estimate is $126.2M.
